Investor conference appearances put ICU Medical in focus
ICU Medical (ICUI) is drawing investor attention after announcing that management will participate in the Wells Fargo 21st Annual Healthcare Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in September 2026.
The recent conference schedule comes as ICU Medical shares trade at US$175.10, after a 1 month share price return of 5.63% and a 90 day share price return of 29.33%. The 1 year total shareholder return of 37.83% contrasts with a 5 year total shareholder return that is still down 14.08%, indicating that momentum has strengthened in the short term while longer term holders remain underwater.
Scan how ICU Medical compares with other hospital suppliers by reviewing our hand picked list of solid balance sheet and fundamentals (50 results) for ideas with similar fundamentals and financial resilience.
ICU Medical now trades at a discount of about 10% to analyst targets and roughly 18% to an estimated intrinsic value after a sharp recent run. Is that a genuine margin of safety, or a signal of market caution?
Most Popular Narrative: 8.6% Undervalued
At $175.10, ICU Medical trades modestly below a widely followed fair value estimate of $191.50, which is built around pump demand, margin progress, and free cash flow.
Manufacturing network consolidations, portfolio optimization, and realization of integration synergies from the Smiths Medical acquisition are driving visible improvements in gross margin, while further benefits are expected once remaining plant transitions complete over the next year, sustained gross margin expansion supports higher profitability.
Want to see what really sits behind that fair value gap? The narrative focuses on steady top line expansion, sharper margins, and a richer earnings profile. The numbers provide additional detail.
Result: Fair Value of $191.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ICU Medical still faces pressure from tariffs and regulatory scrutiny, which could weigh on margins and delay the improvements that underpin the current valuation story.
Find out about the key risks to this ICU Medical narrative.
Another View on ICU Medical’s Valuation
The earlier fair value work points to ICU Medical trading about 18% below an estimated intrinsic value of $212.28 based on future cash flows. That SWS DCF model also flags the stock as undervalued. Is this a cushion against forecast risk, or simply a different way of looking at the same expectations?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
If this mix of risks and rewards around ICU Medical feels finely balanced, consider reviewing the details for yourself by starting with the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond ICU Medical?
If you stop with ICU Medical, you may miss other compelling setups. Use the Simply Wall St screener to surface stocks that better match your goals and risk comfort.
- Target resilient balance sheets and steady fundamentals with our carefully curated list of solid balance sheet and fundamentals (50 results) that filters for financially sturdy companies.
- Hunt for potential value opportunities by scanning the 46 high quality undervalued stocks that highlights stocks trading below their assessed worth on key metrics.
- Spot potential future winners early by reviewing the 20 high quality undiscovered gems that focuses on under-the-radar companies with strong financial profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com